Navigation Links
NPS Pharmaceuticals Reports Third Quarter 2007 Financial Results, Revises Financial Guidance
Date:11/1/2007

to fund operations for the next two to three years.

Pipeline Update

GATTEX

Nycomed has confirmed to NPS its commitment to license GATTEX for development and commercialization outside of North America. Under the terms of the agreement announced in September 2007, Nycomed will now pay NPS the $25 million balance of the $35 million up-front payment due NPS for the rights to develop and market GATTEX outside North America. In October 2007, NPS announced top-line results of the Phase 3 study of GATTEX in patients with short bowel syndrome (SBS). The company has requested a meeting to discuss the next steps in the drug's regulatory approval process with the FDA this year. NPS believes GATTEX could generate U.S. sales of between $150 and $250 million in this indication.

NPS is also running pre-clinical studies of GATTEX in support of a pediatric IND in necrotizing enterocolitis. NEC affects 12,000 neonates annually in the U.S. and mortality approaches 50% in infants weighing less than fifteen-hundred grams. Additional preclinical studies in chemotherapy-induced gastrointestinal mucositis will be initiated very soon. Chemotherapy-induced GI mucositis affects over 500,000 cancer patients in the U.S. annually.

Cinacalcet

NPS recently announced that Kirin Pharma has received approval to market cinacalcet HCl in Japan. This regulatory event triggered a $2 million milestone payment to NPS.

PREOS

In September 2007, the FDA granted orphan drug status for PREOS as a treatment for hypoparathyroidism. The company is currently supporting a two-year study with PREOS in patients with hypoparathyroidism. The study was initiated by Dr. John Bilezikian at Columbia University and is now 96% enrolled.

The company believes that as a result of recent fundraising activities, sales of non-core assets and the GATTEX partnership with Nycomed, it now has the financial resources to fund the continued U.S. development of PREOS in a variety of ind
'/>"/>

SOURCE NPS Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
4. Sonic Foundry reports GAAP loss as Q2 revenues rise
5. Fiserv reports $113.5 million in Q1 profit
6. Third Wave reports net loss of $18.9M for 2006
7. Musicnotes reports 45 percent growth in 2006
8. Sonic Foundry reports net loss, higher revenue
9. Sonic Foundry reports first cash-positive quarter
10. Merge Healthcare reports $10.8M net loss in Q3
11. Third Wave reports $5.2M third quarter loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging ... to serve the wound care market. , Free report ... was restructured with a seasoned management team and Board, ...
(Date:1/14/2014)... 2014 iLab Solutions, the leader in core ... Director of Product Strategy. In this role, Michelle will work ... to guide in the development of iLab products. Her main ... possible benefit to the scientific community by offering the most ...
(Date:1/14/2014)... 14, 2014 Global Record Systems, ... information technology solutions for patients, physicians, the biopharmaceutical ... announced today the signing of a three-year Research ... Drug Administration (FDA). This initiative is designed ...
(Date:1/14/2014)... 2014 Kerr Corporation, a leading manufacturer of ... how-to information about dual arch impressions on its dental blog. ... Impressions,” the blog entry serves up a list of tips ... step-by-step demonstration by Dr. David Little as he crafts a ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... Inc. (NYSE Amex: PIP ) announced today ... its recombinant protective antigen (rPA) anthrax vaccine program.  PharmAthene ... process for the bulk drug substance of its vaccine ... US-based manufacturing facility at Diosynth RTP.   Activities to ...
... 2011 Caliper Life Sciences, Inc. (NASDAQ: ... Inc., an innovative sequencing service provider based in Gaithersburg, ... the 5500xl, SOLiD 4, and Ion Torrent Personal Genome ... will initially focus on sample preparation for exome, whole ...
... June 27, 2011 ,   ReportsnReports ... , Report in its store Browse the complete ... Report now! Search 75000+ Market Research,Reports ... Reports Report Summary Eliminate unnecessary ...
Cached Biology Technology:PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer 2PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer 3EdgeBio Selects Caliper's Sample Preparation Suite for High Throughput and Benchtop Sequencing Workflows 2ReportsnReports - Daptomycin - Comprehensive Patent Search 2ReportsnReports - Daptomycin - Comprehensive Patent Search 3ReportsnReports - Daptomycin - Comprehensive Patent Search 4ReportsnReports - Daptomycin - Comprehensive Patent Search 5
(Date:4/23/2014)... mammals, ravens form different types of social relationships ... also form strict dominance relations. From a cognitive perspective, ... ability in daily social life ("knowing who is nice ... have with each other sets the stage for "political" ... this study have been published in the scientific journal ...
(Date:4/23/2014)... leading a 2 million Food Standards Agency (FSA) project ... and industry workers. , Norovirus outbreaks can rapidly ... batch of frozen strawberries infected 11,000 people in Germany, ... of which strains cause infection and which foods are ... , Researchers will produce data that will help the ...
(Date:4/22/2014)... secret to get your child to behave at the dinner ... Cornell study published in Eating Behaviors , found that ... bite with their front teeth such as drumsticks, whole apples, ... when these foods had been cut. "They were twice ... other kids," said Brian Wansink, Professor and Director of the ...
Breaking Biology News(10 mins):Ravens understand the relations among others 2Biting vs. chewing 2
... Animals that seem identical may belong to completely different species. ... Gothenburg, Sweden, who have used DNA analyses to discover that ... types of worm. The result is one of many suggesting ... considerably larger than we thought. ,"We could be talking about ...
... the University of Leeds have developed chemicals which kill ... including those resistant to existing drugs. , ... (DHODH) - essential to the growth of the parasite ... Says lead researcher Dr Glenn McConkey, from Leeds, Faculty ...
... Maine, government scientists have figured out how to measure snowfall ... the sun - all the while saving money, energy, and, ... energy-efficient ingenuity was the need to help the National Weather ... snowmelt. The problem was this: While the USGS has ...
Cached Biology News:Animals that seem identical may be completely different species 2New hope for advances in treating malaria 2Measuring snow with a bucket, a windmill, and the sun? 2
... polyclonal antibody raised against a ... Immunogen: K6HF (NP_004684, ... partial recombinant protein with GST ... Number: NM_004693 ...
... The binding specificity and signaling of the ... to be modified by alternative splicing--which has ... SpliceArrays you can perform a classical expression ... the different alternatively spliced forms of the ...
... form of cell suicide, which follows a ... of this process is a cascade of ... participate in a series of reactions that ... and result in the cleavage of protein ...
...
Biology Products: